StockData

Gyre Therapeutics vs Zhengye Biotechnology

GYRE and ZYBT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GYRE and ZYBT compare

Gyre Therapeutics grew revenue faster over the last twelve months (−3.7% versus −37.6% for Zhengye Biotechnology).

Gyre Therapeutics keeps more of each dollar of sales as profit, with a net margin of −33.9% compared with −60.0% at Zhengye Biotechnology.

Gyre Therapeutics scores higher on the StockData Score (11 against 4 for Zhengye Biotechnology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGYREZYBT
Size and price
Market cap$490M–
Share price$4.39$1.43
Change, 1 year−45.7%−33.5%
Change, 5 years−76.6%–
Beta (5Y)1.260.41
Employees61851
StockData Score
Total score11 (better)4
Valuation score1 (better)0
Growth score1 (better)0
Performance score3 (better)1
Health score6 (better)3
Dividend score00
Valuation
P/S4.5×–
P/B4.5×–
FCF yield−1.6%–
Fair value$5.35–
Margin of safety17.9%–
Growth
Revenue growth (TTM)−3.7% (better)−37.6%
Revenue growth, 5Y average41.0%–
Net income growth (TTM)−801%−717% (better)
Profitability
Gross margin93.4% (better)20.5%
Operating margin−14.4% (better)−60.6%
Net margin−33.9% (better)−60.0%
FCF margin−7.2%10.6% (better)
Return on equity−34.9%−26.1% (better)
Return on invested capital−26.6%−18.1% (better)
Financial health
Debt / equity0.000.26 (better)
Interest coverage–−20.7×
Current ratio4.32 (better)1.14
Altman Z-score8.21–
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions7.8%–
Held by insiders93.8%90.7%
Insider net buying, 12 months−$953K–
Short interest, % of float32.4%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.